16:13 EST Cognition Therapeutics (CGTX) files $300M mixed securities shelf
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating
- Cognition reaches full enrollment in expanded access program for CT1812
- Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s
- Cognition Therapeutics price target raisd to $3 from $2 at B. Riley
- Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine